---
title: "Kezar Life Sciences (KZR.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/KZR.US.md"
symbol: "KZR.US"
name: "Kezar Life Sciences"
industry: "Biotechnology"
datetime: "2026-05-20T09:39:18.861Z"
locales:
  - [en](https://longbridge.com/en/quote/KZR.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/KZR.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/KZR.US.md)
---

# Kezar Life Sciences (KZR.US)

## Company Overview

Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases in the United States. The company’s lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b/2 clinical trials in systemic lupus erythematosus. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: 
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 1970-01-01T00:00:00.000Z

**Overall:  (0.00)**

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -1.19 | 188 | - | - | - |
| PB | 0.83 | 71 | 0.60 | 0.54 | 0.31 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-04-26T04:00:00.000Z

Total Analysts: **3**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Hold | 3 | 100% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 7.36 |
| Highest Target | 7.00 |
| Lowest Target | 5.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/KZR.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/KZR.US/norm.md)
- [Related News](https://longbridge.com/en/quote/KZR.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/KZR.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**